Edwards Lifesciences Outlines Vision For Growth At Investor Conference

Core Insights - Edwards Lifesciences Corporation is focused on long-term growth and innovation in structural heart therapies, particularly in TAVR and TMTT [1][2] - The company anticipates strong sales growth in 2025, projecting an increase of 8% to 10% driven by advancements in its technologies [2][5] Growth Drivers - TAVR is expected to generate sales of $4.1 to $4.4 billion in 2025, with a constant currency growth rate of 5% to 7% [4] - TMTT is forecasted to grow by 50% to 60% in 2025, with projected sales of $500 to $530 million [4] - New technologies like the EVOQUE tricuspid valve and PASCAL system are crucial for growth, alongside anticipated regulatory approvals for SAPIEN M3 [4] - The company aims for an average annual sales growth of 10% and double-digit EPS growth starting in 2026, driven by its expanding range of structural heart therapies [4] Financial Outlook - Edwards projects total sales for 2025 to be between $5.6 billion and $6 billion, slightly below the consensus of $5.91 billion [5] - Adjusted earnings per share are expected to be in the range of $2.40 to $2.50, compared to the consensus of $2.44, with gross profit margins of 78% to 79% [5] Market Performance - Edwards Lifesciences' stock increased by 4.21%, reaching $73.15 [6]